Abstract
IntroductionEmicizumab prophylaxis is approved for people of all ages with haemophilia A (HA) including infants and children. Although previous studies have demonstrated the efficacy and tolerability of emicizumab in infants...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have